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Chemoprophylaxis Vaccination (CVac) confers long lasting sterile protection against
homologous parasite strains in humans, and involves inoculation of infectious
sporozoites (SPZ) under drug cover. CVac using the drug chloroquine (CQ) induces pre-
erythrocytic immunity in humans that includes antibody to SPZ and T-cell responses
to liver stage (LS) parasites. The mechanism by which CVac with CQ induces
strong protective immunity is not understood as untreated infections do not confer
protection. CQ kills blood stage parasites, but its effect on LS parasites is poorly
studied. Here we hypothesized that CQ may prolong or perturb LS development
of Plasmodium, as a potential explanation for enhanced pre-erythrocytic immune
responses. Balb/c mice with or without CQ prophylaxis were infected with sporozoite
forms of a luciferase-expressing rodent parasite, Plasmodium yoelii-Luc (Py-Luc). Mice
that received primaquine, a drug that kills LS parasites, served as a positive control of
drug effect. Parasite burden in liver was measured both by bioluminescence and by
qRT-PCR quantification of parasite transcript. Time to appearance of parasites in the
blood was monitored by microscopic analysis of Giemsa-stained thick and thin blood
smears. The parasite load in livers of CQ-treated and untreated mice did not significantly
differ at any of the time points studied. Parasites appeared in the blood smears of
both CQ-treated and untreated mice 3 days after infection. Taken together, our findings
confirm that CQ neither eliminates LS parasites nor delays their development. Further
investigations into the mechanism of CQ-induced protection after CVac are required,
and may give insights relevant to drug and vaccine development.
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Introduction
The most successful vaccination approach against malaria involves immunization with whole
organism, generally by the liver-infective form called sporozoites (SPZ). SPZ attenuated by
radiation (RAS; Nussenzweig et al., 1967; Clyde et al., 1973) or by genetic alterations (GAP;
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Mikolajczak et al., 2010; Vaughan et al., 2010) infect hepa-
tocytes but arrest during liver stage (LS) development and
do not emerge in the blood stream. More recently, exper-
imental infection and drug treatment has achieved impres-
sive protection: in humans, inoculation of SPZ under drug
cover, referred to here as Chemoprophylaxis Vaccination (CVac),
required much lower SPZ doses than RAS to induce ster-
ile immunity that persisted for >2 years in four of six
individuals (Belnoue et al., 2004; Roestenberg et al., 2011).
Chloroquine (CQ) prophylaxis has been studied most exten-
sively as drug cover during CVac, and this regimen generates
preerythrocytic immunity that includes anti-sporozoite anti-
body (Behet et al., 2014) and LS-speciﬁc T-cells in animals
and humans (Belnoue et al., 2004; Renia, 2008; Bijker et al.,
2013).
Chloroquine kills blood stage parasites as they reach the
trophozoite stage of development (Yayon et al., 1983), but the
eﬀect of CQ on LS parasites has received less attention. It is
widely believed that CQ does not aﬀect LS development, allowing
the immune system to encounter the full repertoire of LS anti-
gens. However, the more durable protection achieved with CVac
after ∼16-fold fewer mosquito bites than required for RAS sug-
gests that drug treatment eﬀects might contribute independently
to protection.
The eﬀect of CQ on Plasmodium LS development is not com-
pletely settled. Based on an in vivo infection model, Belnoue
et al. (2004) reported that CQ does not kill Plasmodium LS at
42 h post infection with SPZ. However, the eﬀect of CQ on
later time points including blood stage emergence has not been
studied. Using an in vitro infection model, Fisk et al. (1989)
reported a partial schizonticidal eﬀect of CQ on late LS, but the
CQ dose was relatively high, and had cytotoxic eﬀects on hep-
atocytes as well. Here we report a systematic evaluation of the
eﬀects of therapeutic concentrations of CQ on late LS develop-
ment, using a luciferase expressing P. yoelii parasite in Balb/c
mice.
Materials and Methods
Mice
Female Balb/c mice, 4–6 week old were purchased from Taconic.
Mice were housed in the NIH animal facility under pathogen free
conditions and fed with autoclaved food ad libitum. All exper-
iments were performed once mice reached 16 to 18 weeks of
age. All experiments were approved and performed as per the
guidelines by the Animal Care and Use Committee (ACUC) of
NIAID/NIH.
Parasite and Mosquitoes
Plasmodium yoelii parasites (strain 17XNL), including the
parental line and a transgenic line expressing ﬁreﬂy-luciferase
and GFP (Plasmodium yoelii-Luc, Py-Luc), were maintained
by cycling between Balb/c mice and Anopheles stephensi
mosquitoes. Salivary gland SPZs were harvested on days 14–
18 as described earlier (Ozaki et al., 1984; Guebre-Xabier et al.,
1999).
Infection and Evaluation of LS Development
by Bioluminescence Imaging
Female Balb/c mice (16–18 weeks old) were infected with 15,000
freshly dissected SPZ of Py-Luc in 100 μl of 1X PBS+2% normal
mouse serum by IV injection. Development of LS was moni-
tored by bioluminescence imaging (BLI) at diﬀerent time points
post-infection as described earlier (Mwakingwe et al., 2009;
Miller et al., 2013). Brieﬂy, mice were injected intradermally with
150 μl of Rediject D-Luciferin (Caliper Life Sciences, USA), then
anesthetized with isoﬂurane-anesthesia system 8–10 min later
to allow measurement of bioluminescence and image acquisi-
tion using IVIS-100 animal imager (Caliper Life Sciences, USA).
Bioluminescence images were acquired at the following settings:
15 cm Field of View (FOV), medium binning, and exposure time
of 30–60 s. Quantiﬁcation of luminescence was performed using
the ROI settings of the Living Image 4.4 software (Perkin Elmer,
USA). ROI were drawn around the abdominal area locating the
liver. ROI measurements were expressed as total ﬂux photons per
second (p/s).
Drug Treatment and LS Burden Estimation
by Intravital Imaging
Infected mice comprised three groups that received diﬀerent
treatments in 100 μl of PBS by intraperitoneal (IP) route: one
group received 0.8 mg/mouse of CQ diphosphate (SPZ+CQ;
Sigma; Belnoue et al., 2004): one group received 1.5 mg/mouse
of PQ bisphosphate (SPZ+PQ; Sigma; Putrianti et al., 2009);
one group received PBS without drug (SPZ). Two drug con-
trol groups were also included, whereby mice received CQ
or PQ but no SPZ infection. An additional control group
received no drug and no SPZ. Drug was delivered at the
time of infection (0 hours post infection, hpi) and at 24 hpi.
Bioluminescence images were acquired in vivo with IVIS-100
(Perkin Elmer) at diﬀerent time points after drug injection
indicated in the ﬁgure legends. BLI was performed on whole
livers that had been perfused (10 ml of RNAse free 1x PBS)
and isolated at sequential time points from 40 hpi onward.
Liver samples were also snap-frozen in liquid nitrogen for
qRT-PCR.
Determination of LS Burden by qRT-PCR
Total RNA was extracted from the whole liver as described
earlier (Schussek et al., 2013) using RNeasy mini kit (Qiagen
Inc). cDNA was synthesized using High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystem, Foster City,
CA, USA). Gene expression was measured with 1:40 dilu-
tions of cDNA. Standard curve quantitative RT-PCR was
performed (Bruna-Romero et al., 2001) in a 20 μl vol-
ume, which includes 1X ABI Power SYBR master mix
(Applied Biosystems) and 0.25 μM of either P. yoelii 18S
rRNA primer (forward- GGGGATTGGTTTTGACGTTTT,
reverse- AAGCATTAAATAAAGCGAATA) or mouse β-actin
primers (Forward- GGCTGTATTCCCCTCCAT; reverse-
CCAGTTGGTAACAATGCAAT). PCR reactions were run on
ABI 7500 machine (Applied Biosystems), using the following
conditions: 50◦C for 2 min; 95◦C for 10 min; 40 cycles of 95◦C
for 15 s alternating with 60◦C for 1 min.
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cDNA standards for both 18S rRNA and β-actin were prepared
as 10-fold dilutions (107–103 copies) from puriﬁed PCR product.
Liver of naïve mouse was used as negative control. Parasite load
was normalized to host β-actin as a ratio (absolute copy of Py 18S/
absolute copy of mouse β-actin).
Determination of Prepatent Period
Thick and thin blood smears were collected from the infected
mice at diﬀerent time points starting 42 hpi. Blood smears were
Giemsa-stained and examined with a bright ﬁeld microscope
with 100× oil-immersion objective and by expert slide readers
blinded to the study groups. Blood smears were considered pos-
itive if at least two infected RBCs were found in 100 adjacent
ﬁelds.
Statistical Analysis
Mann–Whitney test was used to compare groups for LS burden
measured by either BLI or qPCR. P ≤ 0.05 was considered statis-
tically signiﬁcant. GraphPad Prism software (version 6) was used
for statistical analysis.
Results
LS Parasites Persist 54 h after SPZ
Inoculation into Untreated Mice
Plasmodium undergoes extensive multiplication during LS devel-
opment, producing tens of thousands of merozoites from an
individual sporozoite. Upon completion of LS development,
merozoites are released into the blood stream as small merozoite-
ﬁlled vesicles called merosomes. To quantify the multiplication
and subsequent release of parasites in the liver, we infected
mice with 1.5 × 104 luciferase expressing Py-Luc SPZ and per-
formed BLI at 40, 44, 48, 54, and 62 hpi. Parasite biomass
increased with time until 44 h and then gradually declined
with the lowest LS parasite burden at 54 hpi (Figures 1 and
2; Supplementary Figure S2). We could detect measurable
luciferase activity in the liver at 54 hpi with an average total
ﬂux of 5.0 × 106 photon/s (Figure 1). By 62 hpi, parasites are
FIGURE 1 | Duration of Plasmodium yoelii-Luc (Py-Luc) liver stage (LS)
growth. Graph representing quantification of total flux from infected and
untreated mice imaged at 40, 44, 48, and 54 h after sporozoites (SPZ)
injection. n = 3 for 40 h, 4 for 44 h, and 5 each for 48, and 54 h. Graph
represents Mean ± SD. Mann–Whitney test was performed and p < 0.05
considered as significant.
detected throughout the body, indicating a blood stage infec-
tion (Supplementary Figure S1E), and any residual parasites in
the liver could not be distinguished from circulating blood stage
parasites.
CQ Neither Kills LS Parasites Nor Delays
Their Development
To evaluate the eﬀect of CQ on developing LS parasites, we
infected mice with 1.5 × 104 Py-Luc SPZ, and then treated
with either CQ (0.8 mg/mouse), PQ (1.5 mg/mouse), or an
equal volume of PBS. Three groups of uninfected mice received
same treatments (CQ, PQ, or PBS) but no SPZ. Imaging of
whole bodies or of isolated livers was performed at 40, 44, 48,
and 54 hpi. CQ-treated (SPZ+CQ) and untreated (SPZ) mice
did not diﬀer signiﬁcantly at any time point (Figures 2 and 3;
Supplementary Figure S2), whereas the SPZ+PQgroup was com-
pletely devoid of any bioluminescence, as expected (Figure 2;
Supplementary Figure S1). Parasite burden estimation with con-
ventional qPCR gave similar results (Figure 2D). At 40 hpi,
bioluminescence appeared lower in SPZ+CQ group than SPZ
group but this trend was not statistically signiﬁcant (p = 0.06;
Figure 2C), and no such trend was observed in the corre-
sponding qRT-PCR measurements at this time point (P = 0.86;
Figure 2D).
To remove inter-subject variability in a second experiment,
we followed individual mice over time, and acquired BLI at
sequential time points. We infected each of 20 mice with SPZ
of Py-Luc; half were treated with CQ while half received an
equal volume of PBS. At 42, 44, 46, and 48 hpi, LS parasite
burden was measured by whole body BLI. We did not observe
signiﬁcant diﬀerences in the parasite burden in the SPZ+CQ
versus SPZ animals at any time point (Supplementary Figures
S3 and S4). In a third experiment, using parental Py-17XNL
infection, we conﬁrmed by qPCR that the LS parasite burden at
48 hpi does not signiﬁcantly diﬀer between SPZ+CQ and SPZ
animals (p = 0.38, Supplementary Figure S5). Both SPZ+CQ
and SPZ mice became blood stage positive at 48 hpi by blood
smear microscopy, further indicating that CQ does not delay LS
development (Figure 4).
Discussion
The eﬀect of CQ on Plasmodium blood stages is well charac-
terized, with the inhibition of heme-polymerase enzyme leading
to accumulation of toxic heme products, and parasite death
(Slater and Cerami, 1992). CQ-CVac generates strong LS-speciﬁc
immune responses and more durable protection at a log-fold
lower SPZ dose as compared to RAS immunization (Clyde et al.,
1973; Bijker et al., 2013). However, it is not clear how CQ treat-
ment helps generate this strong and durable immune response.
One school of thought holds that CQ-CVac allows the complete
development of LS parasites that express a wide array of LS spe-
ciﬁc antigens, prior to killing the parasites in their ﬁrst cycle
of blood stage development; however, untreated Plasmodium
infections also display the full antigen repertoire without induc-
ing sterile preerythrocytic immunity. We hypothesized that
Frontiers in Microbiology | www.frontiersin.org 3 April 2015 | Volume 6 | Article 283
Sahu et al. Chloroquine and Plasmodium liver stages
FIGURE 2 | Effect of CQ on LS parasite at 40 hours post infection
(hpi). Rainbow images of mice infected and untreated (A) or CQ-treated
(B) showing parasite load in liver 40 h after injection of 1.5 × 104 Py-Luc
salivary gland SPZ. Rainbow scale represents radiance (p/s/cm2/sr). (C)
Quantification of total flux from whole body imaging of mice (shown in A
and Supplementary Figure S1). n = 3 for SPZ ( infected and untreated)
and NI (neither infected nor treated) group, four for SPZ+CQ group and
five each for SPZ+PQ and drug control (treated uninfected) groups.
(D) Quantification of LS parasite burden 40 hpi in livers of SPZ (n = 3),
SPZ+CQ (n = 4), and SPZ+PQ (n = 5) mice by qPCR. Graph represents
Py-18S RNA normalized to murine β-actin RNA. Data in (C,D) represents
Mean ± SD, Mann–Whitney test was performed and p < 0.05 considered
as significant. CQ, Chloroquine; PQ, Primaquine; NI, non-infected and
non-treated.
FIGURE 3 | Parasite load in liver at different time points after CQ treatment. Quantification of total flux from whole body imaging of mice (shown in
Supplementary Figure S4). n = 4 for SPZ group at 44 hpi (A), five each for both SPZ and SPZ+CQ at 48 h (B), and 54 h (C) time points. Graph represents
mean ± SD. Mann–Whitney test was performed and p < 0.05 considered as significant.
CQ may have partial or subtle eﬀects on late LS develop-
ment that contribute to enhanced immune responses, but we
ﬁnd no evidence that CQ decreases LS burden or delays LS
development.
The eﬀect of CQ on the LS of Plasmodium has previously
been studied in vivo in a mouse model (Belnoue et al., 2004) and
in vitro by infection of non-human primate hepatocytes (Fisk
et al., 1989). Belnoue et al. (2004) reported that mice treated
with 0.8 mg CQ and untreated mice had similar LS parasite
burden 42 hpi, but did not examine eﬀects beyond this time
point; the CQ dose (∼32 mg/kg) used by Belnoue et al. (2004,
and also by us for this study) was based on earlier work (Orjih
et al., 1982), and is in the dosing range (30–35 mg/kg) used
for children of 10–20 kg body weight (Moore et al., 2011).
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FIGURE 4 | Effect of CQ on prepatent period of Py-Luc. Mice (n = 18)
were infected with 1.5 × 104 Py-Luc salivary gland SPZ and either
CQ-treated (SPZ+CQ; n = 9) or not (SPZ; n = 9). Blood smears (both thick
and thin smears) were collected starting from 48 hpi. Smears were stained
and examined by expert smear reader blinded. Smears are considered
positive if minimum two parasites were found in 100 adjacent fields.
Earlier, Fisk et al. (1989) reported that CQ at 1 μg/ml had
a partial parasiticidal eﬀect in vitro on late LS P. cynomolgi
and P. knowlesi schizonts. However, these drug concentra-
tions were ∼2.5-fold higher than therapeutic concentrations
(0.03–0.4 μg/ml) in humans (Tett et al., 1989; Carmichael et al.,
2003), and had toxic eﬀects on hepatocytes that may have con-
tributed to parasiticidal activity.
We examined the eﬀect of CQ on LS development in vivo by
imaging luciferase expressing P. yoelii parasites in Balb/c mice,
and followed parasite development in the liver, both by BLI
and qPCR, at multiple time points from 40 h through 62 h.
We observed no diﬀerence in the LS parasite load between CQ-
treated (SPZ+CQ) and untreated (SPZ) groups at any time point
during late LS development. Our observations at 42 hpi are con-
sistent with those of Belnoue et al. (2004) and additionally showed
no diﬀerences at 44, 46, 48, and 54 hpi.
We hypothesized that CQ might delay LS development, at
least for a subset of parasites, thereby creating a condition
of prolonged antigen exposure that might enhance LS speciﬁc
immunity. All mice, both SPZ+CQ and SPZ, had parasites
detectable by blood smear microscopy by 48 hpi, suggesting
that there had been no delay in LS development with CQ
treatment. This was further substantiated by similar LS par-
asite burdens in both groups of mice at 48 hpi (Figure 3;
Supplementary Figures S3–S5). Our study cannot exclude the
possibility that a small subset of parasite persist in liver of
SPZ+CQ mice, because emerging blood stage parasites might
mask the presence of LS forms in bioluminescence or qRT-PCR
studies.
The potential eﬀect of CQ to delay the prepatent period has
also been examined in humans as part of CVac trials, using
highly sensitive qPCR techniques to detect, and quantify blood
stage parasites at densities below the sensitivity of microscopy
(i.e, subpatent parasitemia; Roestenberg et al., 2009; Bijker et al.,
2013). During CVac, blood stage parasites are detected by qPCR
at the time expected of untreated individuals (Roestenberg et al.,
2009; Bijker et al., 2013), although a direct comparison of
blood stage parasite burden between CQ-treated and untreated
individuals has not been reported. Similarly, we ﬁnd that blood
stage parasites are detected by microscopy at 48 hpi in both
SPZ+CQ and SPZ mice. A previous study in mice reported that
CQ suppressed blood stage growth during CVac (Peng et al.,
2014), as is observed in human studies (Roestenberg et al.,
2009; Bijker et al., 2013). Our results in mice conﬁrm that CQ
does not delay LS development nor kill LS parasites, and sup-
port the notion that the diminished ﬁrst wave of parasitemia
is likely to be solely due to its eﬀects on blood stage growth,
rather than the eﬀect on the number of parasites released from
liver.
Chloroquine was once widely used as an anti-malarial drug
and was highly eﬀective in clearing blood stage forms of sensi-
tive Plasmodium parasites, but use of CQ has waned decisively
with the global spread of CQ-resistant parasites. Recently, the
impressive immunity observed after CVac has sparked renewed
interest in CQ as a component of whole organism vaccines,
whereby individuals are inoculated with infectious SPZ under
CQ drug cover. However, the mechanisms by which drug treat-
ment converts infectious SPZ into an eﬀective vaccine remain
unclear. Using a luciferase-expressing parasite and an in vivo
mouse infection model, we have systematically evaluated the
eﬀect of CQ on Plasmodium late liver stages. We report that
CQ given at a dose used for CVac studies neither kills nor
delays LS parasite development. However, our study does not
exclude other eﬀects of CQ on Plasmodium LS biology that
might impact immune responses, such as an altered repertoire
of expressed antigens, and hence further investigation is war-
ranted.
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